ZIOPHARM Oncology (ZIOP) Cut to Strong Sell at ValuEngine
Several other research firms also recently weighed in on ZIOP. BidaskClub upgraded shares of ZIOPHARM Oncology from a "strong sell" rating to a "sell" rating in a research note on Thursday, January 4th.
from Biotech News
0 Comments